Tampa General Hospital Cancer Institute

Sorting 1 by

Accepting patients

BGB-11417

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results